Article
Oncology
Ciro Franzese, Beatrice Marini, Davide Baldaccini, Marco Badalamenti, Pierina Navarria, Luisa Bellu, Davide Franceschini, Tiziana Comito, Elena Clerici, Maria Ausilia Teriaca, Maria Massaro, Luciana Di Cristina, Lorenzo Lo Faro, Stefano Tomatis, Marta Scorsetti
Summary: This study confirms the efficacy and safety of SABR for oligoprogression from RCC, with the potential to prolong ongoing systemic therapy and eliminate resistant metastases.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
Patrick Cheung, Samir Patel, Scott A. North, Arjun Sahgal, William Chu, Hany Soliman, Belal Ahmad, Eric Winquist, Tamim Niazi, Francois Patenaude, Gerald Lim, Daniel Yick Chin Heng, Arbind Dubey, Piotr Czaykowski, Rebecca K. S. Wong, Anand Swaminath, Scott C. Morgan, Rupi Mangat, Sareh Keshavarzi, Georg A. Bjarnason
Summary: SRT for oligoprogressive metastatic renal cell carcinoma (mRCC) lesions in patients on tyrosine kinase inhibitor (TKI) therapy showed high local control (LC) and delayed the need to change systemic therapy.
Article
Urology & Nephrology
Shankar Siva, Mathias Bressel, Simon T. Wood, Mark G. Shaw, Sherene Loi, Shahneen K. Sandhu, Ben Tran, Arun A. Azad, Jeremy H. Lewin, Katharine E. Cuff, Howard Y. Liu, Daniel Moon, Jeremy Goad, Lih-Ming Wong, Michael LimJoon, Jennifer Mooi, Sarat Chander, Declan G. Murphy, Nathan Lawrentschuk, David Pryor
Summary: The RAPPORT trial investigated the combination of high-dose precision radiotherapy and a short course of immunotherapy in patients with low-volume metastatic kidney cancer. The results showed that this treatment regimen was well tolerated, with excellent cancer control in known disease sites, and a proportion of patients were free from cancer relapse in the longer term. These findings are encouraging and warrant further investigation.
Article
Clinical Neurology
Leila Maria Da Roz, Geovanne Pedro Mauro, Vinicius de Carvalho Gico, Eduardo Weltman, Evandro Cesar de Souza, Eberval Gadelha Figueiredo, Manoel Jacobsen Teixeira
Summary: This study retrospectively reviewed AVM patients treated with radiation or a combination of radiation and embolization. The results showed that stereotactic radiosurgery plays an important role in AVM treatment and should be preferred whenever possible.
WORLD NEUROSURGERY
(2023)
Review
Urology & Nephrology
Muhammad Ali, Jennifer Mooi, Nathan Lawrentschuk, Rana R. Mckay, Raquibul Hannan, Simon S. Lo, William A. Hall, Shankar Siva
Summary: Stereotactic ablative body radiotherapy (SABR) is a promising treatment modality for primary and metastatic renal cell carcinoma (RCC), offering potential benefits in terms of local control and delaying systemic therapy. It can be safely combined with systemic therapy and provides palliation for brain and spinal metastases.
Article
Medicine, General & Internal
Yunchong Liu, Zhuo Liu, Ran Peng, Ruotao Xiao, Junjie Wang, Hao Wang, Lulin Ma
Summary: The study examines the clinical trial design, treatment, and evaluation indicators of preoperative stereotactic ablative radiotherapy combined with surgery for renal cell carcinoma and vena cava tumour thrombus.
Article
Biochemistry & Molecular Biology
Pawel Polanowski, Aleksandra Nasiek, Aleksandra Grzadziel, Ewa Chmielik, Agnieszka Pietruszka, Krzysztof Skladowski, Katarzyna Polanowska
Summary: This paper presents a case study on the use of radiotherapy and stereotactic boost in the radical treatment of sebaceous carcinoma. The individualized approach showed positive results in the treatment of this rare malignancy.
Article
Urology & Nephrology
Cristina Masini, Cinzia Iotti, Ugo De Giorgi, Roberto Salvatore Bellia, Sebastiano Buti, Francesco Salaroli, Ilaria Zampiva, Renzo Mazzarotto, Claudia Mucciarini, Maria Giuseppa Vitale, Alessio Bruni, Frank Lohr, Giuseppe Procopio, Orazio Caffo, Franco Nole, Franco Morelli, Susanne Baier, Consuelo Buttigliero, Patrizia Ciammella, Giorgia Timon, Emanuela Fantinel, Gabriele Carlinfante, Annalisa Berselli, Carmine Pinto
Summary: This study evaluated the efficacy and safety of stereotactic body radiotherapy (SBRT) in combination with nivolumab in second- and third-line metastatic renal cell carcinoma (mRCC) patients. The results showed that the combination treatment did not provide additional clinical benefits but was safe and showed a good response in the irradiated lesions.
Article
Clinical Neurology
Geovanne Pedro Mauro, Leila Maria Da Roz, Vinicius de Carvalho Gico, Eduardo Weltman, Evandro Cesar de Souza, Eberval Gadelha Figueiredo, Manoel Jacobsen Teixeira
Summary: This study aimed to evaluate whether fractionated radiotherapy (FRT) is more effective than single-dose radiosurgery (SRS) in the treatment of vestibulocochlear schwannomas in patients with type 2 neurofibromatosis (NF2). The results showed that in the NF2 population, FRT may yield worse control rates than SRS. Therefore, it is preferable to avoid fractionated treatment for these patients whenever possible.
WORLD NEUROSURGERY
(2023)
Article
Oncology
Paolo Sogono, Mathias Bressel, Steven David, Mark Shaw, Sarat Chander, Julie Chu, Nikki Plumridge, Keelan Byrne, Nicholas Hardcastle, Tomas Kron, Greg Wheeler, Gerard G. Hanna, Michael MacManus, David Ball, Shankar Siva
Summary: The study showed that single-fraction stereotactic body radiation therapy is safe and effective for patients with oligometastatic disease, reducing the number of attendances and improving efficiency. Patients had high overall survival rates and a significant proportion remained treatment-free for several years after therapy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Ahmed Gawish, Nurlan Abdulayev, Souhir El-Arayed, Burkard Roellich, Hans-Joachim Ochel, Thomas B. Brunner
Summary: This study retrospectively analyzed 48 patients with intracranial meningiomas treated with radiation surgery, and found that SFRT had better local control effects in the treatment of Grade I meningiomas compared to SRS. This may be due to the reduced risk of brain necrosis in large PTVs with SFRT. Therefore, SFRT is a better choice for typical meningioma PTVs.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Hamoun Rozati, Jiarong Chen, Matt Williams
Summary: This study conducted a systematic review and meta-analysis to assess the overall survival of patients with ten or more brain metastases treated with stereotactic radiosurgery. The results showed that patients with ten or more metastases had statistically worse overall survival compared to the control group. However, there was insufficient information to draw conclusions on toxicity.
Article
Oncology
Ahmed Gawish, Burkard Roellich, Hans-Joachim Ochel, Thomas B. Brunner
Summary: This study analyzed the obliteration and re-bleeding rates after linac-based SRS treatment for cerebral AVMs. The results showed that prior embolization had no effect on the obliteration rate and the annual bleeding hazard rates were relatively low. However, asymptomatic abnormalities were detected in 33.9% of patients after imaging.
RADIATION ONCOLOGY
(2022)
Article
Oncology
Brian Keller, Anna M. E. Bruynzeel, Chad Tang, Anand Swaminath, Linda Kerkmeijer, William Chu
Summary: Adaptive MR-guided radiotherapy is emerging as a non-invasive treatment option for renal cell carcinoma, with real-time plan adaptation based on daily MRI anatomy showing improved target coverage and normal tissue sparing. Continued technological innovations are expected to address organ motion challenges and enhance oncologic outcomes, promising a positive clinical impact in the management of renal cell carcinoma.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Naoyuki Kanayama, Toshiki Ikawa, Shingo Ohira, Takero Hirata, Masahiro Morimoto, Kazuhiko Ogawa, Teruki Teshima, Koji Konishi
Summary: This study demonstrates that a significant reduction in brain metastases volume at 6 months post-SRT can predict local control. The dose of 80% of the gross tumor volume (GTV) D80 in the LQ model: alpha/beta = 20 may be a predictive factor for volume reduction.
Article
Oncology
Shankar Siva, Brent Chesson, Mathias Bressel, David Pryor, Braden Higgs, Hayley M. Reynolds, Nicholas Hardcastle, Rebecca Montgomery, Ben Vanneste, Vincent Khoo, Jeremy Ruben, Eddie Lau, Michael S. Hofman, Richard De Abreu Lourenco, Swetha Sridharan, Nicholas R. Brook, Jarad Martin, Nathan Lawrentschuk, Tomas Kron, Farshad Foroudi
Article
Oncology
D. Xing, S. Siva, G. G. Hanna
Article
Urology & Nephrology
Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, Thomas Zilli, Nicholas Van As, Shankar Siva, Andrei Fodor, Piet Dirix, Alfonso Gomez-Iturriaga, Fabio Trippa, Beatrice Detti, Gianluca Ingrosso, Luca Triggiani, Alessio Bruni, Filippo Alongi, Dries Reynders, Gert De Meerleer, Alessia Surgo, Kaoutar Loukili, Raymond Miralbell, Pedro Silva, Sarat Chander, Nadia Gisella Di Muzio, Ernesto Maranzano, Giulio Francolini, Andrea Lancia, Alison Tree, Chiara Lucrezia Deantoni, Elisabetta Ponti, Giulia Marvaso, Els Goetghebeur, Piet Ost
Article
Oncology
Pavel N. Lobachevsky, Nicholas W. Bucknell, Joel Mason, Diane Russo, Xiaoyu Yin, Lisa Selbie, David L. Ball, Tomas Kron, Michael Hofman, Shankar Siva, Olga A. Martin
Editorial Material
Urology & Nephrology
Shankar Siva, Piet Ost, Nicholas Zaorsky, Michael Staehler
Review
Oncology
Nicholas Hardcastle, Olivia Cook, Xenia Ray, Alisha Moore, Kevin L. Moore, David Pryor, Alana Rossi, Farshad Foroudi, Tomas Kron, Shankar Siva
Summary: This study demonstrates the feasibility and effectiveness of real-time treatment plan review using KBP in the TROG 15.03 FASTRACK II trial. The use of KBP improved treatment plan quality in two cases and was considered a useful QA check by all participating centres. Challenges include integrating KBP feedback into clinical timelines and determining appropriate plan quality improvement criteria.
RADIATION ONCOLOGY
(2021)
Review
Oncology
Austin J. Bartl, Mary Mahoney, Mark W. Hennon, Sai Yendamuri, Gregory M. M. Videtic, Kevin L. Stephans, Shankar Siva, Mark K. Farrugia, Sung Jun Ma, Anurag K. Singh
Summary: The adoption of single-fraction stereotactic body radiation therapy for lung tumors has been limited in various institutions, even during the COVID-19 pandemic. Lack of familiarity and concerns about potential toxicities may be reasons for this limitation. To address this issue, a systematic review of prospective studies on single-fraction SBRT was conducted. The review found that the use of single-fraction SBRT showed favorable outcomes in terms of local control and survival among peripheral tumors. Toxicities were generally mild, with a small percentage of patients experiencing severe toxicity. These encouraging results suggest that single-fraction SBRT may be beneficial beyond the current pandemic.
Article
Oncology
Stephanie G. C. Kroeze, Corinna Fritz, Jana Schaule, Oliver Blanck, Klaus Henning Kahl, David Kaul, Shankar Siva, Sabine Gerum, An Claes, Nora Sundahl, Sonja Adebahr, Susanne Stera, Markus M. Schymalla, Nasrin Abbasi-Senger, Daniel Buergy, Michael Geier, Marcella Szuecs, Fabian Lohaus, Guido Henke, Stephanie E. Combs, Matthias Guckenberger
Summary: The study analyzed the safety and efficacy of combining SRT with TT in metastatic cancer patients, finding that interrupting TT during SRT did not significantly affect patient survival or progression. Although some acute and late toxicity related to SRT was observed, severe toxicity rates were low overall. More research is needed to evaluate potential increased toxicity with continuous treatment of EGFR inhibitors or BRAF/MEK inhibitors after SRT in these patients.
Review
Biochemistry & Molecular Biology
Steven David, Jennifer Tan, Shankar Siva, Lama Karroum, Peter Savas, Sherene Loi
Summary: Radiotherapy and immunotherapy are gaining attention in solid tumors, including breast cancer. Radiotherapy can activate immune response to treat distant untreated tumors. Stereotactic Ablative Body Radiotherapy is a non-invasive technique that provides high dose ablative treatment while sparing normal tissues.
Article
Oncology
Shankar Siva, Gavin Jones, Mathias Bressel, Mark Shaw, Sarat Chander, Julie Chu, Nikki Plumridge, Keelan Byrne, Gargi Kothari, Nicholas Hardcastle, Mathieu Gaudreault, Tomas Kron, Greg Wheeler, Michael MacManus, Gerard G. Hanna, David L. Ball, Steven David
Summary: This study investigated the prognostic significance of medical operability and total versus subtotal ablation of all oligometastatic disease sites in patients. The results showed that medical operability was not predictive of survival, while total metastatic ablation was associated with better overall survival and progression-free survival.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Editorial Material
Urology & Nephrology
Davi Chang, Sree Appu, Shankar Siva
Article
Oncology
Shankar Siva, Pitchaya Sakyanun, Tao Mai, Wenchang Wong, Adeline Lim, Joanna Ludbrook, Catherine Bettington, Angela Rezo, David Pryor, Nicholas Hardcastle, Tomas Kron, Braden Higgs, Hien Le, Marketa Skala, Suki Gill, Thomas Eade, Raef Awad, Giuseppe Sasso, Shalini Vinod, Rebecca Montgomery, David Ball, Mathias Bressel
Summary: This article reports on a randomized clinical trial comparing single- versus multifraction stereotactic ablative body radiotherapy (SABR) in patients with oligometastases to the lung. The study found no differences in safety, efficacy, systemic immunogenicity, or survival between the two treatment arms, with single-fraction SABR selected based on cost-effectiveness. The final updated survival outcome analysis showed no differences in overall survival, disease-free survival, or modified disease-free survival between the two arms.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Andrew B. Barbour, Simon Kirste, Anca-Liga Grosu, Shankar Siva, Alexander V. Louie, Hiroshi Onishi, Anand Swaminath, Bin S. Teh, Sarah P. Psutka, Emily S. Weg, Jonathan J. J. Chen, Jing Zeng, John L. Gore, Evan Hall, Jay J. J. Liao, Rohann J. M. Correa, Simon S. Lo
Summary: Patients with localized renal cell carcinoma often have medical comorbidities limiting their surgical candidacy, thus necessitating less invasive treatment options. Stereotactic ablative radiotherapy has emerged as a safe and effective management option with a growing body of evidence supporting its use. This article discusses recent advances in the use of stereotactic ablation radiotherapy for localized renal cell carcinoma, while guiding providers on practical points for patient selection and clinical application.
Article
Respiratory System
Aidan Joseph Cole, Nicholas Hardcastle, Guy-Anne Turgeon, Roshini Thomas, Louis B. Irving, Barton R. Jennings, David Ball, Tomas Kron, Daniel P. Steinfort, Shankar Siva
Article
Oncology
Shankar Siva, Alexander V. Louie, Andrew Warner, Alexander Muacevic, Senthilkumar Gandhidasan, Lee Ponsky, Rodney Ellis, Irving Kaplan, Anand Mahadevan, William Chu, Anand Swaminath, Hiroshi Onishi, Bin Teh, Rohann J. Correa, Simon S. Lo, Michael Staehler